Introduction
============

Myocardial infarction and stroke represent the second and third leading causes of death and disability in the Western world respectively. The majority of cases result from thrombosis or embolism following rupture of unstable coronary and carotid arterial plaques. Development of this pathology is thought to be as a consequence of a combination of a number of risk factors, including age, gender, hypertension, hyperlipidaemia, smoking, diabetes and infections. The atherosclerotic plaque is a dynamic structure that undergoes continuous remodeling of the extracellular matrix during development, and on which its structural integrity is dependent ([@b14-bmi-2007-361]). Lesions including phase 2 and upwards following endothelial injury are prone to rupture ([@b24-bmi-2007-361]). Acute changes within the plaque including active matrix remodeling, intraplaque hemorrhage associated with vascularization and fibrous cap rupture are a prelude to the onset of clinical ischemic events, however, the mechanisms and activation processes leading to this are not fully understood. Angiogenesis occurs within vascular lesions, resulting in formation of a network of capillaries, which extend into the thickened intimal layer associated with atherosclerosis and inflammation, and ultimately increasing susceptibility of the plaque to rupture ([@b15-bmi-2007-361]; [@b16-bmi-2007-361]; [@b11-bmi-2007-361]). The identification of plaque erosion sites rich in proteoglycan expression and associated with vessel occlusion without rupture of the fibrous plaque cap represents a novel pathophysiological basis for atherothrombosis ([@b9-bmi-2007-361]; [@b7-bmi-2007-361]).

Hyaluronan (HA) is a non-sulphated linear glycosaminoglycan consisting of repeating units of (α,1--4)-D-glucuronic acid-(β,1--3)-N-acetyl-D-glucosamine. HA is found in its native state as a high molecular weight polymer (\>10^6^ kDa) in the extracellular matrix of almost all animal tissues and in significant quantities in the skin (dermis and epidermis) and the brain ([@b21-bmi-2007-361]). Apart from its role as an inert viscoelastic lubricant which is essential for healthy joint function ([@b25-bmi-2007-361]), HA has a crucial role in regulation of the angiogenic process. In particular, HA is a potent regulator of vascular endothelial cell (EC) function. Native high molecular weight HA (\>10^6^ KDa) is synthesized by a family of enzymes called HA synthases (HAS), and is anti-angiogenic, inhibiting EC proliferation and migration ([@b26-bmi-2007-361]; [@b5-bmi-2007-361]) as well as capillary formation in a 3D collagen gel model ([@b19-bmi-2007-361]). Degradation products of specific size (3--10 disaccharide units; o-HA) stimulate EC proliferation, migration, sprout formation and result in angiogenesis in the chick chorioallantoic membrane ([@b22-bmi-2007-361], [@b23-bmi-2007-361]; [@b27-bmi-2007-361]). Generation of this 'angiogenic' o-HA, from the naturally occurring HA polymer is mediated by action of the endoglycosidase hyaluronidase (HYAL; [@b13-bmi-2007-361]), in association with tissue damage, and inflammatory disease ([@b26-bmi-2007-361]). The biological functions of HA/o-HA are thought to be initiated through cell surface receptors (particularly, CD44 and RHAMM (receptor for HA mediated motility)), resulting in signal transduction activation and ultimately cell mitogenesis. In vascular EC, both CD44 ([@b17-bmi-2007-361]; [@b23-bmi-2007-361]) and RHAMM ([@b12-bmi-2007-361]), have been identified as potential targets for transduction of o-HA-induced mitogenesis. We have previously demonstrated that o-HA but not native HA induced up-regulation of the immediate early response genes c-jun, jun B, Krox 20, Krox 24 and c-fos in bovine aortic EC (BAEC) ([@b5-bmi-2007-361]). Similarly, o-HA induced rapid CD44 dependent activation of PKC, Raf-1 kinase, MEK-1 and ERK1/2 resulting in mitogenesis in these cells ([@b22-bmi-2007-361]).

Previous studies have demonstrated an increase in expression of hyaluronan in distinct regions of human post-mortem aortic atherosclerotic plaques ([@b9-bmi-2007-361]; [@b18-bmi-2007-361]), although the size of the expressed molecule was not determined. In this manuscript, we have investigated the expression of HA metabolising enzymes and receptors for HA in a series of carotid artery transplants.

Methodology
===========

Carotid artery transplants
--------------------------

Carotid specimens were obtained from dying patients, used for vascular transplants and exhibiting various stages of the atherosclerotic disease process (Phase I--V). Plaque pathology and characteristics including ulcerating, haemorrhagic or eroding regions was determined by anatomo-pathology ([Table 1](#t1-bmi-2007-361){ref-type="table"}).

Western blotting
----------------

Antibodies to the HA receptors, TSG-6 and RHAMM as well as hyaluronidase 1 and 2 and HA synthase 1 and 2, were supplied by our collaborators (Dr. Katalin Mikecz, Chicago, U.S.A., Dr. Eva Turley, Ontario, Canada, Professor Rashmin Savani, Philadelphia, U.S.A. and Dr. Evi Heldin, Uppsala, Sweden respectively). Their activities and specificities have been confirmed previously in detail ([@b1-bmi-2007-361] and references therein). Anti-CD44 was bought from Calbiochem (U.K.). Briefly, tissue samples (50 mg) were lysed and protein separation carried out using SDS-PAGE electrophoresis as described previously ([@b23-bmi-2007-361]). Blots were stained overnight at 4 °C with primary antibodies described above and (Sigma, 1:1000) used as a loading control. Protein concentration was estimated from the band intensity by densitometry. Results are not quantitative and are used only to demonstrate differences in expression as a basis for selection of IHC analysis. All experiments were performed twice and a representative example is shown.

Immunohistochemistry
--------------------

Cellular localization was examined by immunohistochemistry, The Avidin-Biotin-Peroxidase method (ABC Vectastain kit, Vector Laboratories, Peterborough, U.K.) was used for the qualitative demonstration of antigens in tissues. Antibodies described above were used at 1:50 dilution. De-parrafinised 5 μm sections were treated for 10min in a boiling solution of concentrated citric acid (pH 6.0; Vector Laboratories) in a pressure cooker to unmask the antigens. Sections were stained with primary antibodies for 2h at RT, with the appropriate HRP-conjugated secondary antibody for 1h at RT, and then counterstained with haematoxylin. Negative control slides had the primary antibody replaced with PBS or the appropriate IgG pre-immune serum. Specificity of the antibodies has been previously established ([@b1-bmi-2007-361] and [@b2-bmi-2007-361]).

Results
=======

Complicated plaque regions expressed increased concentration of HYAL-1
----------------------------------------------------------------------

Weak expression of HYAL-1 was seen in Western blots of carotid transplants with no evidence of intra-luminal plaques and in those with stable fibrous structures ([Fig. 1a](#f1-bmi-2007-361){ref-type="fig"}; e.g. B and F and [Fig. 1b](#f1-bmi-2007-361){ref-type="fig"} (i); B shown). In contrast, complicated plaque lesions showed higher expression of HYAL-1 ([Fig. 1a](#f1-bmi-2007-361){ref-type="fig"}; e.g. A and H), particularly in areas of inflammation ([Fig. 1b](#f1-bmi-2007-361){ref-type="fig"} (ii) and (iii); A and H shown respectively). HYAL-2 was weakly expressed in normal looking arteries and no difference was seen in plaque lesions (data not included). Only weak expression of HAS1/2 was seen in both normal arteries and non-complicated/complicated regions with no significant differences in neovessel rich/poor areas of intima (data not shown).

RHAMM receptor was identified in neovessels from complicated plaque lesions
---------------------------------------------------------------------------

RHAMM receptor was weakly expressed in normal looking arteries as shown by Western blots ([Fig. 2a](#f2-bmi-2007-361){ref-type="fig"}; e.g. B and F). IHC confirmed a general lack of expression even in adventitial blood vessels ([Fig. 2b](#f2-bmi-2007-361){ref-type="fig"} (i); B shown). Carotid arteries with complicated lesions demonstrated increased staining in Western blots, and strong localization around plaque intimal neovessels ([Fig. 2b](#f2-bmi-2007-361){ref-type="fig"} (ii) and (iii); E shown). The presence of intimal blood vessels was confirmed by staining serial sections with antibodies to CD105 which stained active endothelial cells ([Fig. 2b](#f2-bmi-2007-361){ref-type="fig"} (iv); E shown). No differences in CD44 or TSG-6 expression were found (data not included).

Discussion
==========

New blood vessels may have an active role in plaque metabolic activity and actively promote its growth beyond the critical limits of diffusion from the artery lumen. Later in the progression of the disease, the inherent weakness of newly forming blood vessels could result in development of intra-plaque haemorrhage and instability (Mofidi et al. 2001; [@b8-bmi-2007-361]; [@b11-bmi-2007-361]). In this study, we have demonstrated that HYAL-1, which can depolymerise n-HA to angiogenic fragments, was increased in inflammatory complicated plaque regions. Previous studies have shown that HA was up-regulated in atherosclerotic lesions of apoE deficient mice, although the molecular weight was not determined ([@b4-bmi-2007-361]). In stable lesions, the fibrous cap is enriched with ECM molecules including versican and biglycan, which promote stability, viscoelasticity and inhibit vascular growth.

Rupture sites, however, have almost complete absence of ECM, in particular n-HA, possibly due to increased expression of matrix metalloproteinases ([@b9-bmi-2007-361]). It has been suggested that loss of n-HA corresponds with decreased integrity of the fibrous cap. Plaque erosion sites are distinct from rupture sites in that they contain many more SMC and ECM. These sites also tend to progress to thrombi. A significant increase in HA was found at the erosion site and at the plaque-thrombus interface of eroded vasculature, although the molecular size was not determined. Administration of either high molecular weight or angiogenic fragments (4--16 dissacharides) of HA reduced SMC proliferation and neointima formation in rats after balloon catheter injury suggesting a beneficial effect on developing lesions ([@b3-bmi-2007-361]). In this study, we found no evidence of increased HA synthesis in complicated angiogenic lesions.

In this paper, we show for the first time that the RHAMM receptor is over-expressed in neovessels from complicated plaque regions, and therefore might be responsible for enhanced endothelial cell activation via intracellular signal transduction following binding of o-HA. Evidence has shown that changes in expression of HA and its receptors occur concomitantly with transformation of stable to unstable arterial plaques. Increased expression of HA together with its receptor CD44 were found in rupture-prone areas in post-mortem coronary arteries ([@b6-bmi-2007-361]), whilst increased expression of CD44 was found in atheromatous plaque microvessels, and treatment with anti-CD44/CD44v6 antibodies, reduced EC proliferation *in vitro* ([@b10-bmi-2007-361]). In contrast, we did not find any difference in expression of CD44 between non-complicated and complicated carotid plaques.

In summary, although n-HA is a strong inhibitor of blood vessel growth, and for example, treatment of experimental balloon catheter vascular injury was associated with an inhibition of neointimal formation ([@b20-bmi-2007-361]), it is possible that at injury sites, enzymatic or oxidative/nitrative breakdown of n-HA into smaller fragments, stimulates the growth of new vessels and could encourage plaque haemorrhage and rupture. Thus, changes in metabolism of HA, together with cellular receptor expression might be responsible for key dynamic changes in plaque vulnerability.

Rupture or thrombosis of unstable atherosclerotic plaques in the coronary arteries is a major cause of heart infarction. Development of this disease occurs over a period of decades, during which time, the arterial tissue undergoes a remodeling process making it susceptible to rupture. Hyaluronan is an important component of the arterial matrix, and may be intimately associated with this process.

![HYAL-1 expression was increased in complicated plaque regions. (**A**) Western blots showing relative expression of HYAL-1 in a series of carotid arteries obtained at endarterectomy ([Table 1](#t1-bmi-2007-361){ref-type="table"}). Highest expression was seen in complicated plaques (A and H; [Table 1](#t1-bmi-2007-361){ref-type="table"}). (**B**) IHC showed only weak expression of HYAL-1 in the media of normal looking vessels (i; B), but strong expression in the intimal neovessels (ii; A) and inflammatory regions (iii; H) of complicated plaques.](bmi-2007-361f1){#f1-bmi-2007-361}

![RHAMM expression was increased in complicated plaque regions. (**A**) Western blots showing relative expression of RHAMM in carotid arteries obtained at endarterectomy ([Table 1](#t1-bmi-2007-361){ref-type="table"}). Highest expression was seen in complicated plaques (C and E; [Table 1](#t1-bmi-2007-361){ref-type="table"}), but RHAMM was also expressed in non-complicated plaques (D and G). (**B**) IHC showed only weak expression of RHAMM in the media of normal looking vessels (I, B), but strong expression in the intimal neovessels (ii and iii; E) of complicated plaques. Endothelial cells of neovessels in complicated plaques demonstrated staining of CD105 (iv; E).](bmi-2007-361f2){#f2-bmi-2007-361}

###### 

Anatomo-pathological characteristics of plaques used in study.

      Sex   Age   Plaque description
  --- ----- ----- --------------------------------------------------------------------------------------------------------------
  A   m     69    Advanced, Complicated with thrombosis, inflammation +++, angiogenesis, active, focal necrosis, calcification
  B   m     68    Small plaque, lipidic core, inflammation ++
  C   m     79    Advanced Complicated with thrombosis, rupture, calcification, inflammation +++, angiogenesis, active
  D   m     75    Normal, type I, thickenning of intima
  E   f     86    Advanced, active, lipidic core, inflammation +++, angiogenesis, focal necrosis
  F   f     76    Normal, thickenning of intima
  G   m     56    Normal, thickenning of intima
  H   m     74    Advanced, complicated, calcified plaque, inflammation +, angiogenesis
  I   m     70    Advanced, active plaque, lipidic core, inflammation +++, angiogenesis, focal necrosis, small calcifications
  J   m     82    Small plaque, calcification, inflammation ++, angiogenesis, erosion
  K   m     66    Advanced, complicated plaque, calcification, inflammation +++, angiogenesis, rupture, lipidic core
